Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSC-1255 Alone or With Hydroxychloroquine in Advanced Solid Tumors
NCT04678648Phase 1Recruiting
- Sponsor
- RasCal Therapeutics
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RSC-1255 in solid tumor, lung cancer, colon cancer and 2 more, sponsored by RasCal Therapeutics. Primary endpoints: Maximum Tolerated Dose at 30 months and Recommended Phase 2 Dose at 12 months. Started Mar 2021; status: recruiting.
02
Drugs
RSC-1255
03
Conditions
solid tumorlung cancercolon cancerglioblastoma (GBM)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04678648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678648.